Bank of America Securities Maintains a Buy Rating on Incyte Corporation (INCY), Sets a $104 PT

Incyte Corporation (NASDAQ:INCY) is one of the best affordable biotech stocks to invest in now. In a report released on September 15, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Incyte Corporation (NASDAQ:INCY) and set a price target of $104.00.

Incyte Corporation (INCY): Among Small-Cap Healthcare Stocks Hedge Funds is Buying

Incyte Corporation (NASDAQ:INCY) reported total revenues of $1.216 billion in its fiscal Q2 2025 results, up 16% year-over-year. Total product revenues for the quarter reached $1.059 billion, up 17% year-over-year.

Incyte Corporation (NASDAQ:INCY) is a biopharmaceutical company that discovers, develops, and commercializes proprietary therapeutics, focusing on oncology, hematology, inflammation, and autoimmunity therapeutic areas.

While we acknowledge the potential of INCY to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than INCY and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.